抗癌治疗的耐药性仍然是开发癌症治愈方案的主要障碍。尽管有希望的联合化疗治疗和新颖的免疫疗法已经改善了患者的预后，但对这些治疗的抗药性仍然知之甚少。对表观基因组失调的新见解显示了它如何促进肿瘤生长和对治疗的抗药性。通过改变基因表达的控制，肿瘤细胞可以逃避免疫细胞的识别，忽略凋亡提示以及逆转由化疗药物引起的DNA损伤。在本章中，我们总结了癌症进展和治疗过程中表观遗传重构的数据，以及这些表观遗传变化如何被临床靶向治疗来克服抗药性。版权所有© 2023 Elsevier Inc.。

Resistance to cancer treatments remains a major barrier in developing cancer cures. While promising combination chemotherapy treatments and novel immunotherapies have improved patient outcomes, resistance to these treatments remains poorly understood. New insights into the dysregulation of the epigenome show how it promotes tumor growth and resistance to therapy. By altering control of gene expression, tumor cells can evade immune cell recognition, ignore apoptotic cues, and reverse DNA damage induced by chemotherapies. In this chapter, we summarize the data on epigenetic remodeling during cancer progression and treatment that enable cancer cell survival and describe how these epigenetic changes are being targeted clinically to overcome resistance.Copyright © 2023 Elsevier Inc. All rights reserved.